Company: BCS
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0000312069-25-000114
Chunk: 655

Company: BARCLAYS PLC
Filing Date: 2025-02-13
Form: 20-F
Chunk 655
---
            |            |                 |     |                     |     |                                            |     |
| Other disclosure matters                      |                        |                                  |            |            |                 |     |                     |     |                                            |     |

42 Barclays PLC (the Parent company) Total income Dividend received from subsidiaries Dividends received f rom subsidiaries of £ 3,087 m ( 2023 : £ 2,818 m, 2022 : £ 2,797 m) relates to dividends rec eived from Barclays Execution Services Limited £ 115 m, Barclays Principal Investments Limited £ 215 m, Barclays Bank UK PLC £ 975 m and Barclays Bank PLC £ 1,782 m. Other income Other income of £ 1,183 m ( 2023 : £ 1,174 m, 2022 : £ ( 654) m expense) includes £ 990 m ( 2023 : £ 985 m, 2022 : £ 905 m) of income received from gross coupon payments on Barclays Bank PLC and Barclays Bank UK PLC-issued AT1 securities, net fee and commission income from subsidiaries £ 135 m ( 2023 : £ 139 m, 2022 : £ 114 m) and foreign exchange and fair value gains of £ 58 m ( 2023 : £ 50 m, 2022 : £( 1,673 )m loss). Total assets and liabilities I nvestment in subsidia ries The investment in subsidiaries of £ 63,315m ( 2023 : £ 64,461m ) predominantly relates to investments in the ordinary shares of Barclays Bank PLC of £ 36,340m ( 2023 : £ 36,340m ) and their AT1 securities of £ 9,616 m ( 2023 : £ 10,757 m), as well as investments in the ordinary shares of Barclays Bank UK PLC of £ 14,245m ( 2023 : £ 14,245m ) and their AT 1 securities of £ 2,435m ( 2023 : £ 2,439m ). The decrease of £ 1,146m during the year resulted from net redemptions of AT1 holdings. Impairment in subsidiaries At the end of each reporting period an impairment review is undertaken in respect of investment in the ordinary shares of subsidiaries. Where impairment may be indicated a test of the carrying value against the recoverable value is performed; impairment being indicated where the investment exceeds the recoverable amount